D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial. - D-cycloserine enhancement of exposure therapy

niversity Utrecht0 个研究点开始时间: 2010年8月19日最近更新: 2014年10月27日

适应症

试验速览

暂无简介。

•- Patients with DSM-IV criteria for PD+AGO
•- Male and female, aged between 18-55years old.
•- Female patients of childbearing potential must use reliable method of contraception and not be planning a pregnancy during the study period (in case of doubt a pregnancy test is provided).
•- Written informed consent.
•- Eligible for exposure therapy.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients with:
•- comorbid psychiatric disorder (severe major depressive disorder, bipolar disorder, psychosis, dependence and/or abuse of alcohol/drugs during the past three months)
•- Mental deficiency
•- Inability to adequately read or speak Dutch
•- (a history of) neurological disease (i.e. neurovascular disease, movement disorders, seizures, dementia), renal or liver abnormalities
•- A history of allergies, adverse reactions or rash on medication
•- Currently taking benzodiazepines during the day since benzodiazepines might hamper therapy effect (use of stable dosage of evening medication is allowed)
•- Pregnancy or breastfeeding at the time of the study (in case of doubt a pregnancy test is provided).
•- Use of isoniazide.
•- Use of variable dosages of antidepressiva (SSRI's or TCA's). (The use of a fixed dosage is NOT an exclusion criterium, but will be registered).
•- An unsuccessful evidence based behavioral therapy for panic disorder during the past 12 months (therapy resistant patients).

发起方

niversity Utrecht